Brokerages Set $45.00 Target Price for Immunic (NASDAQ:IMUX)

Shares of Immunic (NASDAQ:IMUX) have earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Brokers have set a twelve-month consensus price objective of $45.00 for the company, according to Zacks. Zacks has also assigned Immunic an industry rank of 51 out of 256 based on the ratings given to related companies.

Separately, Chardan Capital started coverage on shares of Immunic in a research note on Thursday, July 11th. They issued a “buy” rating and a $40.00 target price on the stock.

IMUX traded down $0.48 during trading on Friday, reaching $13.10. The company’s stock had a trading volume of 42,564 shares, compared to its average volume of 176,969. Immunic has a 1 year low of $6.00 and a 1 year high of $390.00. The firm has a market capitalization of $13.87 million, a price-to-earnings ratio of -0.37 and a beta of 3.69.

Immunic Company Profile

Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.

Featured Article: How to build a Fibonacci channel

Get a free copy of the Zacks research report on Immunic (IMUX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.